Clinical pharmacokinetics of nimesulide

Clinical Pharmacokinetics

Volumn 35, Issue 4, 1998, Pages 247-274

  Bernareggi, Alberto ^a,b  

^a Boehringer Ingelheim Italia SpA   (Italy)

^b Boehringer Mannheim Italia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DRUG METABOLITE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG TRANSFORMATION; FECES; HUMAN; LIVER FAILURE; ORAL DRUG ADMINISTRATION; PLASMA CLEARANCE; PRIORITY JOURNAL; SUPPOSITORY; TABLET; URINARY EXCRETION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; MALE; SULFONAMIDES;

EID: 0031753851     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199835040-00001     Document Type: Article

References (94)

1. Davis R, Brogden RN. Nimesulide: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994; 48 (3): 431-54
2. Rabasseda X. Nimesulide: un farmaco antiinfiammatorio che inibisce selettivamente la cicloossigenasi 2. Drugs Today 1996; 32 Suppl. I/II: 1-24
3. Famaey JP. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm Res 1997; 46: 437-46
4. Rabasseda X. Safety profile of nimesulide: ten years of clinical experience. Drugs Today 1997; 33 (1): 41-50
5. Taniguchi Y, Ikesue A, Yopkoyama K, et al. Selective inhibition by nimesulide, a novel non-steroidal anti-inflammatory drug, with prostaglandin endoperoxide synthase-2 activity in-vitro. Pharm Sci 1995; 1: 173-5
6. Tavares IA, Bishai PM, Bennett A. Activity of nimesulide on constitutive and inducible cyclooxygenase. Arzneimforsch Drug Res 1995; 45: 1-3
7. Patrignani P, Panara MR, Sciulli MG, et al. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 1997; 48 (4): 623-31
8. Patrignani P, Panara MR, Santini G, et al. Differential inhibition of the cyclooxygenase activity of prostaglandin endoperoxide synthase isozymes in vitro and ex vivo. 10th International Conference on Prostaglandins and Related Compounds [abstract]. 1996 Sept 22-27; Vienna; 115
9. Vago T, Bevilacqua M, Norbiato G. Effect of nimesulide action time dependence on selectivity towards prostaglandin G/H synthase/cyclooxygenase activity. Arzneimforsch Drug Res 1995; 45: 4-6
10. Bianco S, Robuschi M, Gambaro G, et al. Bronchial inflammation and NSAIDs. Drug Invest 1991; 3 Suppl. 2: 33-8
11. Tofanetti O, Casciarri I, Cipolla PV, et al. Effect of nimesulide on cyclo-oxygenase activity in rats' gastric mucosa and inflammatory exudate. Med Sci Res 1989; 17: 745
12. Cipollini F, Mecozzi V, Altilia F. Endoscopic assessment of the effects of nimesulide in the gastric mucosa: comparison with indomethacin. Curr Ther Res 1989; 45: 1042-8
13. Grossman CJ, Wiseman J, Lucas FS, et al. Inhibition of constitutive and inducible cyclo-oxygenase activity in human platelets and mononuclear cells by NSAIDs and COX 2 inhibitors. Inflamm Res 1995; 44: 253-7
14. Vane JR, Botting RM. Overview: mechanisms of action of anti-inflammatory drugs. In: Vane JR, Botting J, Botting R, editors. Improved non-steroid anti-inflammatory drugs. COX-2 Enzyme Inhibitors. Amsterdam: Kluwer Academic Publishers/William Harvey Press, 1996: 1-27
15. Bevilacqua M, Vago T, Baldi G, et al. Nimesulide decreases superoxide production by inhibiting phosphodiesterase type IV. Eur J Pharmacol 1994; 268: 415-23
16. Bevilacqua M, Vago T, Beretta A. Nimesulide as inhibitor of superoxide anions (O2-) production by human polymorphonuclear leukocytes. Pain Reproduct 1988; 31: 265-72
17. Capecchi PL, Ceccatelli L, Beermann U, et al. Inhibition of neutrophil function in vitro by nimesulide. Preliminary evidence of an adenosine-mediated mechanism. Arzneimittel forschung 1993; 43: 992-6
18. Capsoni F, Venegoni E, Minonzio F, et al. Inhibition of neutrophil oxidative metabolism by nimesulide. Agents Actions 1987; 21: 121-9
19. Dallegri F, Dapino P, Ottonello L, et al. Suppression of neutrophil chloramine production by nimesulide: a possible contribution to the anti-inflammatory activity of the drug. Drug Invest 1991; 3 Suppl. 2: 75-8
20. Ottonello L, Dapino P, Pastorino G, et al. Nimesulide as a downregulator of the activity of neutrophil myeloperoxidase pathway: focus on the histoprotective potential of the drug during inflammatory processes. Drugs 1993; 46 Suppl. 1: 29-33
21. Ottonello L, Dapino P, Dallegri E. Inactivation of α-1 proteinase inhibitor by neutrophil metalloproteinases: crucial role of the myeloperoxidase system and effects of the anti-inflammatory drug nimesulide. Respiration 1993; 60: 32-7
22. Ottonello L, Dapino P, Scirocco MC, et al. Sulphonamides as anti-inflammatory agents: old drugs for new therapeutic strategies in neutrophilic inflammation? Clin Sci 1988; 88: 331-6
23. Dallegri F, Ottonello L, Dapino P, et al. Effect of nonsteroidal anti-inflammatory drugs on the neutrophil promoted inactivation of α-1-proteinase inhibitor. J Rheumatol 1992; 19: 419-23
24. Dallegri F, Ottonello L, Dapino P, et al. The anti-inflammatory drug nimesulide rescues α-1-proteinase inhibitor from oxidative inactivation by phagocytosing neutrophils. Respiration 1992; 19: 1-4
25. Dallegri F, Patrone F, Ballestrero A, et al. Inactivation of neutrophil-derived hypochlorous acid by nimesulide: a potential mechanism for the tissue protection during inflammation. Int J Tissue React 1990; 12 (2): 107-11
26. Dallegri F, Ottonello L, Gatti F, et al. Neutrophil oxidative responses. Cell-directed and scavenging actions of the anti-inflammatory drug nimesulide. Drug Invest 1991; 3 Suppl. 2: 71-4
27. Berti F, Rossoni G, Buschi A, et al. Antianaphylactic and antihistamine activity of the nonsteroidal anti-inflammatory compound nimesulide in guinea-pig. Arzneimittel forschung 1990; 40: 1011-6
28. Casolaro V, Meliota S, Marino O, et al. Nimesulide, a sulfonanilide nonsteroidal anti-inflammatory drug, inhibits mediator release from human basophils and mast cells. J Pharmacol Exp Ther 1994; 276: 1375-85
29. Verhoeven AJ, Tool ATJ, Kuijpers TW, et al. Nimesulide inhibits platelet-activating factor synthesis in activated human neutrophils. Drugs 1991; 46 Suppl. 1: 52-8
30. Pelletier JP, Martel-Pelletier J. Effects of nimesulide and naproxen on the degradation and metalloprotease synthesis of human osteoarthritic cartilage. Drugs 1993; 46 Suppl. 1: 34-9
31. Bernareggi A. The pharmacokinetic profile of nimesulide in healthy volunteers. Drugs 1993; 46 Suppl. 1: 64-72
32. Olive G, Rey E. Effect of age and disease on the pharmacokinetics of nimesulide. Drugs 1993; 46 Suppl. 1: 73-8
33. Castoldi D, Monzani V, Tofanetti O. Simultaneous determination of nimesulide and hydroxynimesulide in human plasma and urine by high-performance liquid chromatogtaphy. J Chromat B 1988; 425: 413-8
34. Bernareggi A, Castoldi D, Nava ML, et al. Linear pharmacokinetics of oral nimesulide in healthy male volunteers treated with 25, 50 and 100mg [Internal Report 02/PKB/98]. Boehringer Mannheim Italia, 1998. (Data on file)
35. Remuzzi G, Gaspari F, Taiocchi L. Development of micromethods to study the pharmacokinetic profile for brodimoprim and nimesulide in small volumes of biological fluids. Helsinn Healthcare, 1991. (Data on file)
36. Abbiati G, Rigoldi M, Parisi S, et al. Farmacocinetica e biodisponibilità di nimesulide β-ciclodestrina granulato nel volontario sano. Giorn Ital Ric Clin Terap 1996; 17: 1-4
37. Pandya KK, Satia MC, Modi IA, et al. High-performance thinlayer chromatography for the determination of nimesulide in human plasma, and its use in pharmacokinetic studies. J Pharm Pharmacol 1997; 49: 773-6
38. Giachetti C, Tenconi A. Determination of nimesulide and hydroxynimesulide in human plasma by high performance liquid chromatography. Biomed Chromatogr 1998; 12: 50-6
39. Lücker PW. Study on the pharmacokinetics (food/drug interaction) and relative bioavailability of three different treatments with nimesulide in 18 healthy male volunteers [TSD No. 5565E]. Helsinn Healthcare, 1992. (Data on file)
40. Lücker PW. Report on the pharmacokinetics and relative bioavailability/bioequivalence of three different nimesulide formulations in 18 healthy male volunteers [TSD No. 5356E]. Helsinn Healthcare, 1991. (Data on file)
41. Alessandrini A, Ballarin E, Bastianon A, et al. Confronto di biodisponibilità tra due diverse forme farmaceutiche orali equidosate di nimesulide in volontari sani. Clin Ter 1986; 118: 177-82
42. Scheen A. Open, randomized, crossover, bioequivalence study of three different formulations of nimesulide, after single oral dose administration in 24 healthy subjects [TSD No. 7215E]. Helsinn Healthcare, 1997. (Data on file)
43. Lücker PW. Report of the study on the pharmacokinetics of nimesulide and its main metabolite 4-OH-nimesulide after oral administration of three different doses in healthy male volunteers [TSD No. 5781E]. Helsinn Healthcare, 1993. (Data on file)
44. De Caro G. Studio comparativo di farmacocinetica e biodisponibilità nell'uomo su formulazioni a base di nimesulide per uso orale (cpr 100mg) e rettale (supposte da 200mg) delle ditte LPB (Mesulid®) e BBR (Aulin®) in somministrazione singola e ripetuta [TSD No. 5437E]. Helsinn Healthcare, 1989. (Data on file)
45. Bernasconi PC. Pharmacokinetics of nimesulide: relative bioavailability of the rectal versus the oral administration. A single and repeated dose study in healthy volunteers [TSD No. 5252E]. Helsinn Healthcare, 1989. (Data on file))
46. Gandini R, Montalto C, Castoldi D, et al. First dose and steady-state pharmacokinetics of nimesulide and its 4-hydroxy metabolite in healthy volunteers. Farmaco 1991; 46: 1061-79
47. Ugazio AG, Guarnaccia S, Berardi M, et al. Clinical and pharmacokinetic study of nimesulide in children. Drugs 1993; 46 Suppl. 1: 215-8
48. Pulkkinen M. Nimesulide in dysmenorrhoea. Drugs 1993; 46 Suppl. 1: 129-33
49. 14C [TSD No. 3007E]. Helsinn Healthcare, 1976; 181-210. (Data on file)
50. 14C]nimesulide after single oral dose administration in 6 healthy male volunteers [TSD No. 5755E]. Helsinn Healthcare, 1993. (Data on file)
51. 14C]nimesulide in man following a single oral administration [TSD No. 7277E]. Helsinn Healthcare, 1997. (Data on file)
52. Brambilla A, Maffei Facino R. Metabolismo del farmaco anti-infiammatorio nimesulide nell'uomo [thesis]. Milan: Faculty of Pharmacy, University of Milan, 1989
53. Maffei Facino R, Carini M, Stefani R, et al. In vitro metabolism of the antiinflammatory drug nimesulide in man: simultaneous determination of the main urinary metabolites by HPLC with UV-DAD detection. Proceedings of the 7th Meeting on Recent Developments in Pharmaceutical Analysis (RDPA '97); 1997 Sep 16-22; Isola d'Elba, 28
54. Castoldi D. Escrezione urinaria della nimesulide dopo somministrazione unica al volontario sano [INternal report]. Boehringer Mannheim Italia, 1989. (Data on file)
55. Casciarri I, Bernareggi A. Disposition of total radioactivity and plasma levels of nimesulide and OH-nimesulide in rats after intravenous and oral administration [Report No. 2/PK/91]. Boehringer Mannheim Italia, 1991. (Data on file)
56. Lin JH, Cocchetto DM, Duggan DE. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 1987; 12: 402-32
57. Verbeeck RK. Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 1990; 19 (1): 44-66
58. Brouwers J, de Smet P. Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 1994; 27 (6): 462-85
59. Graham GG, Champion GD, Day RO, et al. Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis. Clin Pharmacol Ther 1977; 22: 410-20
60. Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Clin Pharmacokinet 1997; 33 (3): 184-213
61. Davies NM. Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin Pharmacokinet 1995; 28 (2): 100-14
62. Davies NM. Clinical pharmacokinetics of tiaprofenic acid and its enantiomers. Clin Pharmacokinet 1996; 31 (5): 331-47
63. Davies NM, Anderson KE. Clinical pharmacokinetics of naproxen. Clin Pharmacokinel 1997; 32 (4): 268-93
64. Pulkkinen MO, Vuento M, Macciocchi A, et al. Distribution of oral nimesulide in female genital tissues. Biopharm Drug Disp 1991; 12: 113-7
65. Lignière GC, Tamborini U, Panarace G, et al. La nimesulide nel liquido sinoviale di paziente con artrite reumatoide. Farmaci Terapia 1990; 7 (3): 173-6
66. Vilageliu J. Nimesulide: evaluation of protein binding and the effects of possible displacers [TSD No. 3545E]. Helsinn Healthcare, 1983. (Data on file)
67. Bree F, Nguyen P Urien S, et al. Nimesulide binding to components within blood. Drugs 1993; 46 Suppl. 1: 83-90
68. Milvio 1984. Confronto di biodisponibilità tra due diversi lotti con massa witepsol [TSD No. 4038.1.I]. Helsinn Healthcare, 1984. (Data on file)
69. Maffei Facino R, Carini M, Brambilla A, et al. Metabolism of nimesulide in man and radical scavenging activity of its main metabolites [abstract]. 3rd Interscience World Conference on Antirheumatics, Analgesics, Immunomodulators; 1989 Mar 15-18; Monte Carlo, 244
70. Maffei Facino R, Carini M, Aldini G. Antioxidant activity of nimesulide and its main metabolites. Drugs 1993; 46 Suppl. 1: 15-21
71. Pirovano R. Study of the capacity of the test article BBR 2335/7 to induce gene mutations in strains of Salmonella typhimurium [RBM Exp. No. 880312]. Boehringer Mannheim Italia, 1988. (Data on file)
72. Pirovano R. Study of the capacity of the test article BBR 2395 to induce gene mutations in strains of Salmonella typhimurium [RBM Exp. No. 890685]. Boehringer Mannheim Italia, 1989. (Data on file)
73. Brodie B, Lowman E, Burns J, et al. Observations on the antirheumatic and physiologic effects of phenylbutazone and some comparisons with cortisone. Am J Med 1954; 16: 181-90
74. Runkel R, Forchielli E, Sevelius H, et al. Nonlinear plasma level response to high doses of naproxen. Clin Pharmacol Ther 1974; 15: 261-6
75. Lin JH, Hooke KF, Yeh KC, et al. Dose-dependent pharmacokinetics of diflunisal in rats: dual effects of protein binding and metabolism. J Pharmacol Exp Ther 1985; 235: 402-6
76. Schärli AF, Brülhart K, Monti T. Pharmacokinetics and therapeutic study with nimesulide suppositories in children with post-operative pain and inflammation. J Int Med Res 1990; 18: 315-21
77. Gupta SK, Prakash J, Awor L, et al. Anti-inflammatory activity of topical nimesulide gel in various experimental models. Inflamm Res 1996; 45: 590-2
78. Inveresk Clinical Research International. A comparative kinetic study of nimesulide following administration of an oral formulation and a topical formulation to 18 male volunteers [TSD No. 7224]. Helsinn Healthcare, 1998. (Data on file)
79. Berardesca E. Evaluation of skin irritation and sensitization potential of different nimesulide topical formulations by repeated insult patch test in healthy volunteers [TSD No. 6103]. Helsinn Healthcare, 1998. (Data on file)
80. Saillant G, Multicenter, double-blind, parallel group study comparing the efficacy and tolerability of nimesulide gel 3% vs. placebo in the treatment of benign ankle sprains [TSD No. 7218]. Helsinn Healthcare, 1998. (Data on file)
81. Bourgeois P, Multicenter, double-blind, parallel group study comparing the efficacy and tolerability of nimesulide gel 3% vs. placebo in the treatment of tendinitis of the upper limb [TSD No. 7219]. Helsinn Healthcare, 1998. (Data on file)
82. Lücker PW. Study on the pharmacokinetics (single and multiple dose) of nimesulide in 10 elderly subjects [TSD No. 5619E]. Helsinn Healthcare, 1992. (Data on file)
83. Pontiroli AE. Report on the pharmacokinetics of nimesulide in elderly patients with normal and elevated creatinine plasma concentrations after single and repeated doses [TSD No. 5520E]. Helsinn Healthcare, 1991. (Data on file)
84. Fillastre JP. Pharmacokinetics of nimesulide after single oral dose in patients with moderate renal insufficiency [TSD No. 4871E]. Helsinn Healthcare, 1991. (Data on file)
85. Fouarge M. Pharmacokinetic profile of nimesulide and its OH-metabolite in plasma and urine in 10 subjects with moderate renal failure during repeated oral administration [TSD No. 5611E]. Helsinn Healthcare, 1992. (Data on file)
86. Olive G. Pharmacokinetics of nimesulide after single oral administration to healthy subjects and those with hepatic insufficiency [TSD No. 5498E]. Helsinn Healthcare, 1993. (Data on file)
87. Perucca E. Drug interactions with nimesulide. Drugs 1993; 46 Suppl. 1: 79-82
88. Fouarge M. Pharmacokinetic interaction study between nimesulide and glibenclamide after single dose cross-over administration in 12 healthy subjects [TSD No. 5687E]. Helsinn Healthcare, 1993. (Data on file)
89. Ugazio G. Pharmacokinetic interaction study between nimesulide tablets and cimetidinc tablets after single dose administration to 12 healthy volunteers [TSD No. 5691E]. Helsinn Healthcare, 1993. (Data on file)
90. Ugazio G. Pharmacokinetic interaction study between nimesulide tablets and Maalox suspension after single dose administration to 12 healthy volunteers [TSD No. 5692E]. Helsinn Healthcare, 1993. (Data on file)
91. Steinhauslin F, Munafo A, Buclin T, et al. Renal effects of nimesulide in furosemide-treated subjects. Drugs 1993; 46 Suppl. 1: 257-62
92. Auteri A, Bruni F, Pasqui AL, et al. Pharmacokinetics and pharmacodynamics of slow-release theophylline during treatment with nimesulide. Int J Clin Pharmacol Res 1991; 11: 211-8
93. Lücker PW. Report of the study on the possible drug-drug interaction of warfarin and nimesulide in 12 healthy male volunteers [TSD No. 5686E]. Helsinn Healthcare, 1993. (Data on file)
94. Baggio E, Maraffi F, Montalto C, et al. A clinical assessment of the potential for pharmacological interaction between nimesulide and digoxin in patients with heart failure. Drugs 1993; 46 Suppl. 1: 91-4